April W. Armstrong, MD, MPH, discusses emerging therapies in oral systemics for the treatment of plaque psoriasis and shares developments in TYK2 inhibition.
Back
The Latest Breakthroughs in Emerging Oral Systemic Treatments for Plaque Psoriasis
An expert in dermatology provides insight on the development of TYK2 inhibitors for the management of plaque psoriasis and reviews treatment approaches using oral systemic therapy for patients.
The Latest Breakthroughs in Emerging Oral Systemic Treatments for Plaque Psoriasis
Episodes
All
All
Dr April W. Armstrong reviews key findings from the phase 3 POETYK PSO-1 and POETYK PSO-2 clinical trials evaluating the use of deucravacitinib for the treatment of plaque psoriasis.
An expert in dermatologic conditions examines laboratory requirements for initiating deucravacitinib in patients with moderate-to-severe plaque psoriasis and the impact of deucravacitinib on the treatment landscape.
April W. Armstrong, MD, MPH, shares her experience using oral systemic treatments in clinical practice for the management of plaque psoriasis.
Dr April W. Armstrong comments on patient selection for oral systemic treatments for plaque psoriasis management.
An expert in dermatology provides insight on approaching treatment in patients with plaque psoriasis who have a low BSA involvement, but with symptoms that present in difficult-to-treat areas.
Advertisement
Advertisement
Trending on HCPLive
1
Atacicept and Upstream Immune Targeting in IgAN With Richard Lafayette, MD
2
Culprits in Perioperative Allergy, With Kimberly Blumenthal, MD
3
Enlicitide’s FDA Approval for LDL-C Reduction and the CORALreef Outcomes Trial
4
Prior Authorization, Precision Medicine, and Eczema Remission, With Jason Hawkes, MD
5